The window Houston has been waiting on is almost open.
Houston is the largest medical city in the country, and that matters for what comes next. The Texas Medical Center concentrates more clinical and research capacity in a single zip-code radius than any other metropolitan area in the world — MD Anderson, Houston Methodist, Baylor College of Medicine, Memorial Hermann, the University of Texas Health Science Center. The national peptide directory exists because the patients asking about peptide therapy in Houston are not, by and large, casual buyers. They are sophisticated, often already inside a concierge medicine or executive-health relationship, and they want to know whether the compounds they have read about can be delivered the right way in their own city.
The regulatory answer is moving. On April 16, 2026, the Federal Register carried notice of the FDA's intent to review the Category 2 classification covering BPC-157, KPV, TB-500, and MOTs-C. The Pharmacy Compounding Advisory Committee meets July 23–24, 2026, to weigh evidence that 503A compounding pharmacies — the licensed facilities that produce these compounds under physician prescription — should be permitted to continue and expand their work. That single meeting will shape the next decade of how anti-aging and longvity protocols are delivered to patients in Houston, in Dallas, and across the rest of the country.
Houston's market structure means the practitioners best positioned to serve patients after reclassification are not boutique storefronts. They are physicians embedded in existing endocrinology, internal medicine, plastic surgery, and concierge-medicine practices who have prepared their compounding partnerships in advance and who understand the regulatory categories at issue — bulk drug substances, 503A versus 503B distinctions, USP <797> sterile compounding standards, MedWatch reporting obligations. The Houston physician you want to be working with already knows the difference between a 503A pharmacy and a research-grade vendor, and treats the distinction as non-negotiable.
The line between a legitimate Houston clinic and a grey-market reseller is sharper than the marketplace tries to make it look. A legitimate clinic prescribes under a physician's DEA registration, sources from a state-licensed 503A compounding pharmacy, documents the clinical indication in a chart note, and never sells peptides as a retail product. Anything else is operating outside federal law — regardless of how polished the branding looks. This directory exists to document the first category and ignore the second.